Clareo Health | Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes
Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
18–69
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Glycosylated haemoglobin (HbA1c) below or equal to 10 procent based on central laboratory results
Diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12 months prior to screening
Body Mass Index (BMI) between 18.0 and 27.0 kg/m\^2 (both inclusive)
Diagnosed with type 2 diabetes mellitus for at least 12 months prior to screening
Treated with insulin for the past 3 months prior to screening
Body Mass Index (BMI) between 22.0 and 35.0 kg/ m\^2 (both inclusive)
You may not be if
Subject with a history of significant multiple drug allergies or with a known allergy or suspected allergy to the trial product or any medicine chemically related to the trial product,as judged by the Investigator.
Subject with a history of or presence of cancer
Any condition that the Investigator and/or Sponsor feels would interfere with study
Therapy with oral antidiabetic drugs within the past 3 months prior to screening
